适配体CAR T细胞克服T细胞耗竭并实现急性髓系白血病的灵活靶向
该研究建立了基于Fab的适配体CAR(AdCAR)T细胞平台,利用抗CD33、抗CD123和抗CLL1适配体分子在体外和体内展示了对急性髓系白血病(AML)细胞系及原代AML细胞的特异性细胞毒性,并首次证明在原代AML共培养中序贯应用不同特异性适配体分子的可行性。研究还表明,通过引入无治疗间隔可对抗慢性T细胞刺激和耗竭。
要点
- AdCAR平台通过适配体分子实现灵活靶向和控制T细胞激活。
- 抗CD33、抗CD123和抗CLL1适配体在体外和体内显示AML特异性细胞毒性。
- 序贯应用不同特异性适配体分子在原代AML共培养中可行。
核心结论
- AdCAR平台可能提供有效策略以改善T细胞耗竭和靶抗原异质性导致的耐药。
研究设计与样本
- 研究建立了基于Fab的适配体CAR(AdCAR)T细胞平台,使用AML细胞系和原代AML细胞长期培养试验进行体外和体内研究。
- 研究未明确报告样本量。
主要发现
- 利用抗CD33、抗CD123和抗CLL1适配体分子在体外和体内展示了AML特异性细胞毒性。
- 首次证明在原代AML共培养中序贯应用不同特异性适配体分子的可行性。
- 通过引入无治疗间隔可对抗慢性T细胞刺激和耗竭。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although the landscape for treating acute myeloid leukemia (AML) patients has changed substantially in recent years, the majority of patients will eventually relapse and succumb to their disease. Allogeneic stem cell transplantation provides the best anti-AML treatment strategy, but is only suitable in a minority of patients. In contrast to B-cell neoplasias, chimeric antigen receptor (CAR) T-cell therapy in AML has encountered challenges in target antigen heterogeneity, safety, and T-cell dysfunction. We established a Fab-based adapter CAR (AdCAR) T-cell platform with flexibility of targeting and control of AdCAR T-cell activation. Utilizing AML cell lines and a long-term culture assay for primary AML cells, we were able to demonstrate AML-specific cytotoxicity using anti-CD33, anti-CD123, and anti-CLL1 adapter molecules in vitro and in vivo. Notably, we show for the first time the feasibility of sequential application of adapter molecules of different specificity in primary AML co-cultures. Importantly, using the AML platform, we were able to demonstrate that chronic T-cell stimulation and exhaustion can be counteracted through introduction of treatment-free intervals. As T-cell exhaustion and target antigen heterogeneity are well-known causes of resistance, the AdCAR platform might offer effective strategies to ameliorate these limitations.
引用
- Nixdorf D, Sponheimer M, Berghammer D, et al. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. Leukemia. 2023. PMID: 37106163. doi:10.1038/s41375-023-01905-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。